Show simple item record

dc.contributor.authorBollag, Wendy B.
dc.contributor.authorGonzales, Joyce N.
dc.date.accessioned2023-10-16T14:11:22Z
dc.date.available2023-10-16T14:11:22Z
dc.date.issued2020-11
dc.identifier.citationBollag, W. B., & Gonzales, J. N. (2020). Phosphatidylglycerol and surfactant: A potential treatment for COVID-19? Medical Hypotheses, 144, Article 110277. https://doi.org/10.1016/j.mehy.2020.110277en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/624830
dc.description.abstractA hypothesis concerning the potential utility of surfactant supplementation for the treatment of critically ill patients with COVID-19 is proposed, along with a brief summary of the data in the literature supporting this idea. It is thought that surfactant, which is already approved by the Food and Drug Administration for intratracheal administration to treat neonatal respiratory distress syndrome in pre-term infants, could benefit COVID-19-infected individuals by: (1) restoring surfactant damaged by lung infection and/or decreased due to the virus-induced death of the type II pneumocytes that produce it and (2) reducing surface tension to decrease the work of breathing and limit pulmonary edema. In addition, a constituent of surfactant, phosphatidylglycerol, could mitigate COVID-19-induced lung pathology by: (3) decreasing excessive innate immune system stimulation via its inhibition of toll-like receptor-2 and -4 activation by microbial components and cellular proteins released by damaged cells, thereby limiting inflammation and the resultant pulmonary edema, and (4) possibly blocking spread of the viral infection to non-infected cells in the lung. Therefore, it is suggested that surfactant preparations containing phosphatidylglycerol be tested for their ability to improve lung function in critically ill patients with COVID-19.en_US
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.url10.1016/j.mehy.2020.110277en_US
dc.subjectCOVID-19en_US
dc.subjectInnate immunityen_US
dc.subjectPhosphatidylglycerolen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSurfactanten_US
dc.titlePhosphatidylglycerol and surfactant: A potential treatment for COVID-19?en_US
dc.typeAbstracten_US
dc.typeArticleen_US
dc.contributor.departmentAugusta Universityen_US
dc.identifier.journalMedical Hypothesesen_US
refterms.dateFOA2023-10-16T14:11:25Z


This item appears in the following Collection(s)

Show simple item record